On May 13, 2025, Larimar Therapeutics, Inc. held its Annual Meeting of Stockholders where Thomas E. Hamilton was elected to the Board, executive compensation was approved, and PricewaterhouseCoopers LLP was ratified as the auditor for fiscal year 2025. The meeting saw 64 million shares eligible to vote, with notable support for all proposals.